Synthesis and antihyperglycemic activity of novel N-acyl-2-arylethylamines and N-acyl-3-coumarylamines

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 7, 2008, Pages 2301-2305

  Dwivedi, Atma P ^a   Kumar, Shailesh ^a   Varshney, Vandana ^a   Singh, Amar B ^a   Srivastava, Arvind K ^a   Sahu, Devi P ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

N Acyl 2 arylethylammines; N Acyl 3 coumarylamines; SLM; STZ

Indexed keywords

ANTIDIABETIC AGENT; AROMATIC AMINE; GLIBENCLAMIDE; GLUCOSE; METFORMIN; N [2(3,4 DIMETHOXYPHENYL)ETHYL] 3 (3 TRIFLUOROMETHYLPHENYL)ACRYLAMIDE; N [2(3,4 DIMETHOXYPHENYL)ETHYL] 3 (4 HYDROXY 3 MET HOXYPHENYL)ACRYLAMIDE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ACTIVITY; DRUG SCREENING; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; RAT; STATISTICAL SIGNIFICANCE; STREPTOZOCIN DIABETES;

ACYLATION; ANIMALS; BLOOD GLUCOSE; COUMARIC ACIDS; DIABETES MELLITUS, EXPERIMENTAL; ETHYLAMINES; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; MODELS, CHEMICAL; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41149159899     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.03.003     Document Type: Article

References (14)

1. Wild S., Roglic G., Green A., Sicree R., and King H. Diabetes Care 27 (2004) 1047
2. American Diabetes Association (ADA) National Dibetes Fact sheet, ADA web site (on line), http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf.
3. Ashiya M., and Smith R.E.T. Nat. Rev. Drug Discov. 6 (2007) 777
4. Zareba G., Serradell N., Castañer R., Davies S.L., Prous J., and Mealy N. Drug Future 30 (2005) 1253
5. Okada Y., Miyauchi N., Suzuki K., Kobayashi T., Tsutsui C., Mayuzumi K., Nishibe S., and Okuyama T. Chem. Pharm. Bull. 43 (1995) 1385
6. Zdero C., Bohmann F., and Niemeyer H.M. Phytochemistry 29 (1990) 205
7. Wakasugi M., Noguchi T., Inoue M., Tawata M., Shindo H., and Onaya T. Prostaglandins Leukot. Essent. Fatty Acids 44 (1991) 233
8. Chatterjee A., and Bhattacharya A. J. Chem. Soc. (1959) 1922
9. Narender T., Shweta S., Tiwari P., Reddy P.K., Khaliq T., Prathipati P., Puri A., Srivastava A.K., Chander R., Agarwal S.C., and Raj K. Bioorg. Med. Chem. Lett. 17 (2007) 1808
10. 3 solution. It was dried over sodium sulfate and evoporated to furnish the desired product, N-[2-(3,4-dimethoxyphenyl)ethyl]-3-(3-trifluoromethyl-phenyl) acrylamide (3h).
11. Typical procedure. A mixture of 3-(4-hydroxy-3-methoxy-phenyl)-acrylic acid (10 mmol), 2-(3,4-dimethoxy-phenyl)-ethylamine (11 mmol), EDC·HCl (12 mmol) triethylamine (12 mmol) in DCM (15 mL) was stirred at 0 °C for 1 h and then at rt for 5 h. Aqueous workup followed by silica gel chromatography afforded N-[2(3,4-dimethoxyphenyl)ethyl]-3-(4-hydroxy-3-met-hoxyphenyl) acrylamide (3g).
12. Typical procedure. The mixture of salicylaldehyde (10 mmol), hippuric acid (11 mmol), acetic anhydride (20 mmol) sodium acetate (12 mmol) was allowed to reflux with continous stirring for 2-4 h. The reaction mixture was brought to rt and cooled at 0 °C. The solid obtained was crystallized with alcohol and was filtered, dried in air to get the pure N-(2-oxo-2H-chromen-3-yl)-3-phenyl-acrylamide (6a).
13. Naomichi F., Michiko Y., and Takeatsu K. Chem. Pharm. Bull. 31 (1983) 156
14. Nomura E., Kashiwada A., Hosoda A., Nakamura K., Morishita H., Tsunod T., and Taniguchia H. Bioorg. Med. Chem. 11 (2003) 3807